Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis

Documenti analoghi

• A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity
  di: Scadding, Glenis, et al.
  Pubblicazione: (2013)
• A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
  di: Price, David, et al.
  Pubblicazione: (2013)
• A new therapy (MP29-02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis
  di: Hellings, Peter, et al.
  Pubblicazione: (2013)
• A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29-02*
  di: Bousquet, Jean, et al.
  Pubblicazione: (2013)
• MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
  di: Scadding, Glenis, et al.
  Pubblicazione: (2015)